Achieving an optimal outcome in the treatment of infections - The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials

被引:43
作者
Li, RC [1 ]
Zhu, M
Schentag, JJ
机构
[1] Genet Inst Inc, 1 Burtt Rd, Andover, MA 01810 USA
[2] Chinese Univ Hong Kong, Fac Med, Dept Pharm, Shatin, Peoples R China
[3] SUNY Buffalo, Sch Pharm, Dept Pharmaceut, Buffalo, NY 14260 USA
[4] Millard Fillmore Hlth Syst, Clin Pharmacokinet Lab, Buffalo, NY USA
关键词
D O I
10.2165/00003088-199937010-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Over the past few decades, the importance of applying pharmacokinetic principles to the design of drug regimens has been increasingly recognised by clinicians. From the perspective of antimicrobial chemotherapy, an improvement in clinical outcome and/or a reduction in toxicity are of primary interest. Before application of these pharmacokinetic theories can be effective, the interrelationships between antimicrobial, pathogen and host factors must be clearly defined. Information regarding the pharmacokinetics of the antimicrobial and the quantification of pathogen susceptibility is required. Even though susceptibility end-points such as minimum inhibitory concentration (MIC) and minimum bactericidal concentration are widely employed, they do not provide any information on dynamic changes of bacterial densities. In this regard, time-kill studies can provide more basic knowledge of the complex bacterial responses to the antimicrobial. Better prediction of these responses can be afforded by the use of mathematical models. More recently, various surrogate end-points employing a combination of suitable pharmacokinetic parameters and susceptibility data, for example the ratio of peak concentration to MIC, the area under the concentration-time curve above the MIC (AUC(>MIC)), the time above the MIG, or the area under the inhibitory curve (AUIC), have been suggested for better prediction of the activity of different classes of antimicrobials. To allow more extensive investigations of the: contribution of pharmacokinetics to the pharmacodynamics of antimicrobials, various in vitro kinetic models have been developed. However, certain limitations exist, and it is necessary to avoid over-interpretation of the data generated by these models. Two important microbial dynamic responses, postantibiotic effect and resistance selection, must be further explored before the full impact of pharmacokinetics on antimicrobial hemotherapy can be depicted. The present paper aims at discussing all the relevant factors and provides some pertinent information on the use of pharmacokinetic-pharmacodynamic principles in antimicrobial therapy.
引用
收藏
页码:1 / 16
页数:16
相关论文
共 82 条
[1]   ORIGIN AND EVOLUTION OF GENES SPECIFYING RESISTANCE TO MACROLIDE, LINCOSAMIDE AND STREPTOGRAMIN ANTIBIOTICS - DATA AND HYPOTHESES [J].
ARTHUR, M ;
BRISSONNOEL, A ;
COURVALIN, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 20 (06) :783-802
[2]   AN INVITRO MODEL FOR MONITORING BACTERIAL RESPONSES TO ANTIBIOTIC AGENTS UNDER SIMULATED INVIVO CONDITIONS [J].
BERGAN, T ;
CARLSEN, IB ;
FUGLESANG, JE .
INFECTION, 1980, 8 :S96-S102
[4]   2 COMPARTMENT KINETIC-MODEL WITH MULTIPLE ARTIFICIAL CAPILLARY UNITS [J].
BLASER, J ;
STONE, BB ;
ZINNER, SH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 15 :131-137
[5]   Markedly different rates and resistance profiles exhibited by seven commonly used and newer β-lactams on the selection of resistant variants of Enterobacter cloacae [J].
Chan, WC ;
Li, RC ;
Ling, JM ;
Cheng, AF ;
Schentag, JJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :55-60
[6]   Experimental efficacy of combined ceftriaxone and amoxycillin on penicillin-resistant and broad-spectrum cephalosporin-resistant Streptococcus pneumoniae infection [J].
Chavanet, P ;
Dalle, F ;
Delisle, P ;
Duong, M ;
Pechinot, A ;
Buisson, M ;
D'Athis, P ;
Portier, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (02) :237-246
[7]  
Craig W.A., 1991, Antibiotics in Laboratory Medicine, V3rd ed., P403
[8]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[9]   POSTANTIBIOTIC EFFECTS IN EXPERIMENTAL-INFECTION MODELS - RELATIONSHIP TO INVITRO PHENOMENA AND TO TREATMENT OF INFECTIONS IN MAN [J].
CRAIG, WA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 :149-158
[10]   PHARMACODYNAMICS OF AMIKACIN INVITRO AND IN MOUSE THIGH AND LUNG INFECTIONS [J].
CRAIG, WA ;
REDINGTON, J ;
EBERT, SC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :29-40